Literature DB >> 21862803

Assessment of mitral valve stenosis by helical MDCT: comparison with transthoracic doppler echocardiography and cardiac catheterization.

Alexander Lembcke1, Tahir Durmus, Yvonne Westermann, Anja Geigenmueller, Benjamin Claus, Craig Butler, Holger Thiele.   

Abstract

OBJECTIVE: We evaluated the precision of helical MDCT for the quantification of mitral valve stenosis (MVS) compared with transthoracic echocardiography (TTE) and cardiac catheterization.
MATERIALS AND METHODS: A total of 28 patients with MVS of differing severity underwent an ECG-gated contrast-enhanced MDCT scan. The mitral valve area (MVA) was determined planimetrically by MDCT and was compared with Doppler TTE using the pressure half-time method and with cardiac catheterization using the Gorlin formula.
RESULTS: Planimetry of the MVA with MDCT was feasible in all cases. The MVA on MDCT (1.88 ± 0.76 cm(2)) was significantly larger than that seen with TTE (1.74 ± 0.75 cm(2); p = 0.039) or cardiac catheterization (1.72 ± 0.67 cm(2); p = 0.037). The correlation between MDCT and TTE (r = 0.90; p < 0.001; limits of agreement, ± 0.65 cm(2)) and that between MDCT and cardiac catheterization (r = 0.86; p < 0.001; limits of agreement, ± 0.76 cm(2)) were good and similar to the correlation between TTE and cardiac catheterization (r = 0.88; p < 0.001; limits of agreement, ± 0.71 cm(2)). The best cutoff level for detecting moderate-to-severe stenosis at MDCT was an MVA of 1.70 cm(2), resulting in a sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 73%, 88%, 82%, 80%, and 83%, respectively, with two false-positive and three false-negative results.
CONCLUSION: The MVA planimetrically determined by MDCT is systematically larger than those calculated by Doppler TTE and cardiac catheterization. However, because of a good correlation between methods and adjustment for the systematic bias, MDCT may allow reliable quantification of MVS and effectual discrimination among severity grades, although discrepancies between methods remain in individual cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862803     DOI: 10.2214/AJR.10.5132

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

Review 1.  Sudden cardiac death from structural heart diseases in adults: imaging findings with cardiovascular computed tomography and magnetic resonance.

Authors:  Song Soo Kim; Sung Min Ko; Sang Il Choi; Bo Hwa Choi; Arthur E Stillman
Journal:  Int J Cardiovasc Imaging       Date:  2016-05-02       Impact factor: 2.357

2.  Quantification of stenotic mitral valve area and diagnostic accuracy of mitral stenosis by dual-source computed tomography in patients with atrial fibrillation: comparison with cardiovascular magnetic resonance and transthoracic echocardiography.

Authors:  Song Soo Kim; Sung Min Ko; Meong Gun Song; Hyun Kun Chee; Jun Suk Kim; Hweung Kon Hwang; Jae-Hwan Lee
Journal:  Int J Cardiovasc Imaging       Date:  2014-07-11       Impact factor: 2.357

Review 3.  Evaluation of the aortic and mitral valves with cardiac computed tomography and cardiac magnetic resonance imaging.

Authors:  Sung Min Ko; Meong Gun Song; Hweung Kon Hwang
Journal:  Int J Cardiovasc Imaging       Date:  2012-11-09       Impact factor: 2.357

4.  Normative MDCT cross-sectional data estimation of superior vena cava and innominate vein in growing children using age as a predictor.

Authors:  Karuna M Das; Tariq S Momenah; Rajvir Singh; Shanker Raja; Abdulrahman AlMoukirish; Mohammad AlZoum; Sven G Larsson
Journal:  Pediatr Cardiol       Date:  2014-03-20       Impact factor: 1.655

5.  Determination of mitral valve area with echocardiography, using intra-operative 3-dimensional versus intra- & post-operative pressure half-time technique in mitral valve repair surgery.

Authors:  Woon-Seok Kang; Jae Won Choi; Joo-Eun Kang; Jin Woo Chung; Seong-Hyop Kim
Journal:  J Cardiothorac Surg       Date:  2013-04-17       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.